Efficacy of Gembrax Followed by Folfirinox Versus Folfirinox Alone in First Metastatic Line Pancreatic Cancer Patients

The aim of this study is to evaluate the efficacy of sequential treatment (Gabrinox) comprising Gembrax regimen (Gemcitabine -Abraxane) followed by the Folfirinox regimen (5FU, Oxaliplatin and Irinotecan) compared to folfirinox alone in patients treated in first metastatic line pancreatic cancer

Trial Details

NCT ID
NCT05065801
Phase
PHASE2
Sponsor
Institut du Cancer de Montpellier - Val d'Aurelle
Status
RECRUITING
Cancer Type
Pancreatic Cancer
Interventions
  • GEMBRAX/FOLFIRINOX Arm A
  • FOLFIRINOX Arm B
Locations (sample)
  • Grenoble, Auvergne-Rhône-Alpes, France|45.17869,5.71479
  • Saint-Etienne, Auvergne-Rhône-Alpes, France|45.43389,4.39
  • Reims, Grand Est, France|49.26526,4.02853
  • Montpellier, Herault, France|43.61093,3.87635
  • Montpellier, Hérault, France|43.61093,3.87635

Key Eligibility Criteria

  • Male or female aged 18 to 75 on the date the consent is signed.
  • Histologically or cytologically proven metastatic pancreatic adenocarcinoma. The definitive diagnosis of pancreatic adenocarcinoma metastases will …
  • One or more metastatic lesion (s) measurable (Recist 1.1) by Thoraco-Abdomino-Pelvic scanner (or hepatic MRI and Thoraco-Abdomino-Pelvic scanner no…
  • Previous treatment (including radiochemotherapy) for the non-metastatic disease authorized if a delay ≥ 6 months between the last treatment and the…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Pancreatic Cancer Trials on Trialify →